SEC Form 4 · accession 0001209191-15-047705
PHARMACYCLICS INC · PCYC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kenneth A Clark
Director
Period of report
May 26, 2015
Accepted (ET)
May 28, 2015 · 7:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000949699
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $49.00 | May 26, 2015 | D | 15,000 | D | — | Nov 9, 2022 | Common Stock | 15,000 | 0 | D |
| Stock Option (Right to Buy)F1 | $61.44 | May 26, 2015 | D | 134 | D | — | Jan 2, 2023 | Common Stock | 134 | 0 | D |
| Stock Option (Right to Buy)F1 | $79.67 | May 26, 2015 | D | 280 | D | — | Apr 1, 2023 | Common Stock | 280 | 0 | D |
| Stock Option (Right to Buy)F1 | $74.48 | May 26, 2015 | D | 3,750 | D | — | May 9, 2023 | Common Stock | 3,750 | 0 | D |
| Stock Option (Right to Buy)F1 | $85.39 | May 26, 2015 | D | 245 | D | — | Jul 1, 2023 | Common Stock | 245 | 0 | D |
| Stock Option (Right to Buy)F1 | $139.89 | May 26, 2015 | D | 159 | D | — | Oct 1, 2023 | Common Stock | 159 | 0 | D |
| Stock Option (Right to Buy)F1 | $108.44 | May 26, 2015 | D | 192 | D | — | Jan 2, 2024 | Common Stock | 192 | 0 | D |
| Stock Option (Right to Buy)F1 | $107.42 | May 26, 2015 | D | 194 | D | — | Apr 1, 2024 | Common Stock | 194 | 0 | D |
| Stock Option (Right to Buy)F1 | $95.08 | May 26, 2015 | D | 3,750 | D | — | May 9, 2024 | Common Stock | 3,750 | 0 | D |
| Stock Option (Right to Buy)F1 | $89.58 | May 26, 2015 | D | 367 | D | — | Jul 1, 2024 | Common Stock | 367 | 0 | D |
| Stock Option (Right to Buy)F1 | $115.80 | May 26, 2015 | D | 284 | D | — | Oct 1, 2024 | Common Stock | 284 | 0 | D |
| Stock Option (Right to Buy)F1 | $124.46 | May 26, 2015 | D | 264 | D | — | Jan 2, 2025 | Common Stock | 264 | 0 | D |
Explanation of responses
- F1Pursuant to terms of the Agreement and Plan of Reorganization (the "Merger Agreement") dated March 4, 2015, by and between the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Oxford Amherst Corporation, a Delaware corporation and a direct wholly owned subsidiary of AbbVie and Oxford Amherst LLC, a Delaware limited liability company and a direct wholly owned subsidiary of AbbVie this option was cancelled in exchange for a cash payment equal to the number of shares subject to the option multiplied by the difference between $261.25 and the exercise price of the option, subject to applicable withholding taxes and pursuant to the procedures set forth in the Merger Agreement.